Document_and_Entity_Informatio
Document and Entity Information | 6 Months Ended | |
Mar. 31, 2014 | 19-May-14 | |
Document and Entity Information | ' | ' |
Entity Registrant Name | 'ACTIVECARE, INC. | ' |
Document Type | '10-Q | ' |
Document Period End Date | 31-Mar-14 | ' |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0001429896 | ' |
Current Fiscal Year End Date | '--09-30 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q2 | ' |
Entity Common Stock, Shares Outstanding | ' | 34,334,067 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Current assets: | ' | ' |
Cash | $295,906 | $223,835 |
Accounts receivable, net | 6,714,732 | 7,345,912 |
Inventory | 768,940 | 1,249,220 |
Prepaid expenses and other | 69,728 | 38,998 |
Total current assets | 7,849,306 | 8,857,965 |
Customer contracts, net | 1,018,005 | 1,434,521 |
Goodwill | 825,894 | 825,894 |
Patents, net | 503,485 | 566,920 |
Property and equipment, net | 518,448 | 570,360 |
Deposits and other assets | 29,594 | 106,950 |
Domain name, net | 11,083 | 11,440 |
Total assets | 10,755,815 | 12,374,050 |
Current liabilities: | ' | ' |
Accounts payable | 4,700,393 | 6,621,234 |
Accounts payable, related-party | 408,424 | 251,386 |
Accrued expenses | 2,927,742 | 1,267,201 |
Derivatives liability | 0 | 795,151 |
Current portion of notes payable | 932,148 | 1,278,585 |
Notes payable, related-party | 85,365 | 1,892,415 |
Dividends payable | 108,290 | 3,471 |
Total current liabilities | 9,162,362 | 12,109,443 |
Notes payable, net of current portion | 636,421 | 1,055,918 |
Total liabilities | 9,798,783 | 13,165,361 |
Preferred stock, $.00001 par value: 10,000,000 shares authorized; 0 and 480,000 shares of Series C; 45,000 and 938,218 shares of Series D; 70,070 and 61,723 shares of Series E; and 5,361 and 0 shares of Series F, respectively | 1 | 15 |
Common stock, $.00001 par value: 50,000,000 shares authorized; 34,334,067 and 21,775,303 shares outstanding, respectively | 343 | 218 |
Additional paid-in capital, common and preferred | 70,725,651 | 62,519,544 |
Accumulated deficit | -69,768,963 | -63,311,088 |
Total stockholders' equity (deficit) | 957,032 | -791,311 |
Total liabilities and stockholders' equity (deficit) | $10,755,815 | $12,374,050 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets Parenthetical (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Condensed Consolidated Balance Sheets Parenthetical | ' | ' |
Preferred stock par value | $0.00 | $0.00 |
Preferred stock shares authorized | 10,000,000 | 10,000,000 |
Preferred stock shares issued | 120,431 | 1,449,941 |
Preferred stock shares outstanding | 120,431 | 1,449,941 |
Common stock par value | $0.00 | $0.00 |
Common stock shares authorized | 50,000,000 | 50,000,000 |
Common stock shares issued | 34,334,067 | 21,775,303 |
Common stock shares outstanding | 34,334,067 | 21,775,303 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements of Operations (USD $) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Revenues: | ' | ' | ' | ' |
Chronic Illness Monitoring Revenue | $814,187 | $4,256,011 | $2,893,654 | $6,209,615 |
Care Services Revenue | 276,764 | 457,113 | 625,555 | 876,801 |
Total revenues | 1,090,951 | 4,713,124 | 3,519,209 | 7,086,416 |
Cost of revenues: | ' | ' | ' | ' |
Chronic Illness Monitoring Cost of Revenue | 2,300,187 | 3,123,637 | 3,492,001 | 4,585,423 |
Care Services Cost of Revenue | 216,014 | 746,097 | 518,239 | 1,467,624 |
Total cost of revenues | 2,516,201 | 3,869,734 | 4,010,240 | 6,053,047 |
Gross profit (deficit) | -1,425,250 | 843,390 | -491,031 | 1,033,369 |
Selling, general and administrative (including $1,002,196, $73,783, $1,574,390, and $1,502,502, respectively, of stock-based compensation) | 2,885,504 | 2,300,860 | 5,595,205 | 4,872,224 |
Research and development | 47,516 | 266,672 | 122,806 | 468,713 |
Total operating expenses | 2,933,020 | 2,567,532 | 5,718,011 | 5,340,937 |
Loss from operations | -4,358,270 | -1,724,142 | -6,209,042 | -4,307,568 |
Gain on derivatives liability | 0 | 7,360 | 479,737 | 45,697 |
Loss on induced conversion of debt | 0 | 0 | -114,098 | 0 |
Interest expense, net | -171,422 | -767,391 | -1,440,498 | -1,790,983 |
Loss on disposal of property and equipment | -4,216 | 0 | -4,216 | 0 |
Other income | 37,838 | 13,113 | 40,205 | 15,438 |
Total other expense, net | -137,800 | -746,918 | -1,038,870 | -1,729,848 |
Net loss from continuing operations | -4,496,070 | -2,471,060 | -7,247,912 | -6,037,416 |
Gain from discontinued operations | ' | 20,731 | 0 | 6,370 |
Net loss | -4,496,070 | -2,450,329 | -7,247,912 | -6,031,046 |
Deemed dividend on conversion of preferred stock to common stock | 0 | 0 | -2,234,924 | 0 |
Dividends on preferred stock | -181,810 | -74,432 | -346,833 | -133,974 |
Net loss attributable to common stockholders | ($4,677,880) | ($2,524,761) | ($9,829,669) | ($6,165,020) |
Continuing operations | ($0.14) | ($0.55) | ($0.33) | ($1.33) |
Discontinued operations | ' | $0 | ' | $0 |
Net loss per common share | ($0.14) | ($0.55) | ($0.33) | ($1.33) |
Weighted average common shares outstanding - basic and diluted | 33,494,000 | 4,654,000 | 29,375,000 | 4,650,000 |
Statements_of_Operations_Paren
Statements of Operations Parenthetical (USD $) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Statements of Operations Parenthetical | ' | ' | ' | ' |
Compensation expense paid in stock or amortization of stock options and warrants | $1,002,196 | $73,783 | $1,574,390 | $1,502,502 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements of Cash Flows (USD $) | 6 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Cash flows from operating activities: | ' | ' |
Net loss | ($7,247,912) | ($6,031,046) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 586,151 | 612,218 |
Gain on derivatives liability | -479,737 | -45,697 |
Stock-based compensation expense | 1,292,190 | 1,502,502 |
Stock and warrants issued for services | 282,200 | 0 |
Stock issued for interest expense | 837,625 | 257,362 |
Amortization of debt discounts | 562,428 | 480,614 |
Loss on induced conversion of debt | -114,098 | 0 |
Loss on disposal of property and equipment | -4,216 | 0 |
Changes in operating assets and liabilities: | ' | ' |
Change in accounts receivable | 631,180 | -5,365,288 |
Change in inventories | 480,280 | -476,057 |
Change in prepaid expenses and other assets | -45,630 | -20,394 |
Change in accounts payable | -1,763,803 | 1,447,011 |
Change in accrued expenses | 1,483,290 | 2,942,913 |
Change in deposits | 77,355 | -51,584 |
Net cash used in operating activities | -3,186,069 | -4,745,947 |
Cash flows from investing activities: | ' | ' |
Purchases of property and equipment | -58,145 | -267,410 |
Net cash used in investing activities | -58,145 | -267,410 |
Cash flows from financing activities: | ' | ' |
Proceeds from the sale of preferred stock, net | 3,580,771 | 0 |
Proceeds from related-party notes payable, net | 865,666 | 1,990,799 |
Proceeds from notes payable, net | 500,000 | 3,041,746 |
Principal payments on related-party notes payable | -893,666 | -191,831 |
Principal payments on notes payable | -576,376 | -315,130 |
Payment of dividends | -160,110 | 0 |
Net cash provided by financing activities | 3,316,285 | 4,525,584 |
Net increase (decrease) in cash | 72,071 | -487,773 |
Cash, beginning of the period | 223,835 | 529,839 |
Cash, end of the period | 295,906 | 42,066 |
Supplemental Disclosure of Cash Flow Information: | ' | ' |
Cash paid for interest | 115,390 | 469,749 |
Non-Cash Investing and Financing Activities: | ' | ' |
Related-party notes payable converted to common stock | 1,782,738 | ' |
Notes payable converted to preferred stock | 633,254 | ' |
Issuance of stock for loan origination fees | 370,633 | ' |
Liability to issue shares of common stock for loan origination fees | 234,793 | ' |
Dividends on preferred stock | 273,150 | 151,660 |
Issuance of stock for dividends | 68,254 | 35,411 |
Reclassification of derivatives liability to equity | 0 | 4,484,801 |
Issuance of preferred stock for accrued liabilities | 0 | 865,552 |
Issuance of derivatives liability | $0 | $514,643 |
1_Organization_and_Nature_of_O
1. Organization and Nature of Operations | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
1. Organization and Nature of Operations | ' |
1. Basis of Presentation | |
The unaudited interim condensed consolidated financial statements of ActiveCare, Inc. (the “Company” or “ActiveCare”) have been prepared in accordance with Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“US GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying interim condensed consolidated financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2014 and September 30, 2013, and the results of its operations and its cash flows for the three and six months ended March 31, 2014 and 2013. These financial statements should be read in conjunction with the annual consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013. The results of operations for the three and six months ended March 31, 2014 may not be indicative of the results for the full fiscal year ending September 30, 2014. | |
During fiscal year 2013, the Company completed a 10-for-1 reverse common stock split, and all periods presented have been retroactively adjusted to reflect the reverse common stock split. | |
Going Concern | |
The Company continues to incur negative cash flows from operating activities and recurring net losses. The Company had negative working capital as of March 31, 2014 and September 30, 2013. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |
In order for the Company to eliminate substantial doubt about its ability to continue as a going concern, it must improve gross margins, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management’s plans with respect to this uncertainty include raising additional capital by issuing debt or equity securities and increasing the sales of the Company’s services and products. During the six months ended March 31, 2014, the Company (1) completed the sale of Series F convertible preferred stock (“Series F preferred stock”) for net proceeds of $3,580,771, after considering $675,229 of related costs; (2) converted $2,326,801 of debt and accrued interest to common stock; (3) converted $574,592 of debt and accrued interest to Series F preferred stock; and (4) converted $83,473 of debt and accrued interest to Series E preferred stock. There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to offset operating losses. If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and may have to cease operations. | |
Use of Estimates in the Preparation of Financial Statements | |
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the balance sheet dates and the reported amounts of revenues and expenses for the reporting periods. Actual results could differ from these estimates. | |
Fair Value of Financial Instruments | |
The Company measured the fair values of its assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the condensed consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature and liquidity of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair value because the underlying instruments are at interest rates which approximate current market rates. |
2_Discontinued_Operations
2. Discontinued Operations | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
2. Discontinued Operations | ' | |||
2. Discontinued Operations | ||||
In June 2013, the Company sold the assets and liabilities of its reagents segment. This segment was engaged in the business of manufacturing and marketing medical diagnostic stains, solutions and related equipment to hospitals and medical testing labs. The purchaser was a former employee. | ||||
The Company no longer holds any ownership interest in the reagents segment and has ceased incurring costs related to its operations and development. The sale included all applicable segment assets and liabilities including, accounts receivable, inventory, accounts payable, property, equipment and leased equipment. | ||||
As a result of the sale of the reagents business, the Company has reflected this segment as discontinued operations in the condensed consolidated financial statements for the three and six months ended March 31, 2013. The following table summarizes certain operating data for discontinued operations for the three and six months ended March 31, 2013: | ||||
Three months ended | Six months ended | |||
31-Mar-13 | 31-Mar-13 | |||
Revenues | $ 130,029 | $ 254,499 | ||
Cost of revenues | (71,739) | (169,599) | ||
Gross margin | 58,290 | 84,900 | ||
Selling, general and administrative expense | (37,559) | (78,530) | ||
Gain from discontinued operations | $ 20,731 | $ 6,370 |
3_EarningsPerShareTextBlock
3. EarningsPerShareTextBlock | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
3. EarningsPerShareTextBlock | ' | |||
3. Net Loss per Common Share | ||||
Net loss per common share is computed by dividing net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding and the weighted-average dilutive common share equivalents outstanding. The computation of net loss per common share does not assume exercise or conversion of securities that would have an anti-dilutive effect. | ||||
Common share equivalents consist of shares of common stock issuable upon the exercise of stock options, stock purchase warrants and the conversion of convertible preferred stock or debt instruments into common stock. As of March 31, 2014 and 2013, there were 16,841,563 and 9,687,052 outstanding common share equivalents, respectively, that were not included in the computation of diluted net loss per common share as their effect would be anti-dilutive. The anti-dilutive common stock equivalents outstanding consisted of the following as of: | ||||
31-Mar-14 | 31-Mar-13 | |||
Common stock options and warrants | 10,598,576 | 4,136,887 | ||
Series C convertible preferred stock | - | 480,000 | ||
Series D convertible preferred stock | 225,000 | 4,207,715 | ||
Series E convertible preferred stock | 559,737 | - | ||
Series F convertible preferred stock | 5,361,000 | - | ||
Convertible debt | 80,000 | 822,250 | ||
Restricted shares of common stock | 17,250 | 40,200 | ||
Total common stock equivalents | 16,841,563 | 9,687,052 | ||
4_Description_of_New_Accountin
4. Description of New Accounting Pronouncements Not yet Adopted | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
4. Description of New Accounting Pronouncements Not yet Adopted | ' |
4. Recent Accounting Pronouncements | |
The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and has concluded that the future adoption of any such pronouncements will not have a material impact on the Company’s financial position, results of operations, or liquidity. |
5_Inventory
5. Inventory | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
5. Inventory | ' |
5. Inventory | |
Inventory is recorded at the lower of cost or market, cost being determined using the first-in, first-out (“FIFO”) method. Inventory is for the Chronic Illness Monitoring segment and consists of diabetic supplies. The Company writes down inventory due to obsolescence and excessive quantities to estimated net realizable value. Due to competitive pressures and technological innovation, it is possible that estimates of net realizable values could change in the near term. As of March 31, 2014 and September 30, 2013, inventory was $768,940 and $1,249,220, respectively. |
6_Customer_Contracts_Disclosur
6. Customer Contracts Disclosure | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
6. Customer Contracts Disclosure | ' | |||
6. Customer Contracts | ||||
During fiscal year 2012, the Company recorded customer contracts of $2,369,882 acquired in its purchase of 4G Biometrics, LLC and Green Wire, LLC and affiliates. The Company is amortizing the customer contracts over their estimated useful lives (through 2015). Amortization expense for each of the six-month periods ended March 31, 2014 and 2013 was $416,516. As of March 31, 2014 and September 30, 2013, accumulated amortization was $1,351,877 and $935,361, respectively. The Company’s future customer contract amortization as of March 31, 2014, is as follows: | ||||
Years Ending September 30, | ||||
2014 | $ 359,296 | |||
2015 | 658,709 | |||
$ 1,018,005 | ||||
7_Patents
7. Patents | 6 Months Ended | ||||
Mar. 31, 2014 | |||||
Notes | ' | ||||
7. Patents | ' | ||||
7. Patents | |||||
The Company is amortizing its patents over their remaining useful lives (through 2018). Amortization expense for each of the six-month periods ended March 31, 2014 and 2013 was $63,436. As of March 31, 2014 and September 30, 2013, accumulated amortization was $418,893 and $355,458, respectively. The Company’s future patent amortization as of March 31, 2014, is as follows: | |||||
Years Ending September 30, | |||||
2014 | $ 63,435 | ||||
2015 | 126,870 | ||||
2016 | 126,870 | ||||
2017 | 126,870 | ||||
2018 | 59,440 | ||||
$ 503,485 | |||||
8_Property_and_Equipment
8. Property and Equipment | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
8. Property and Equipment | ' | |||
8. Property and Equipment | ||||
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are determined using the straight-line method over the estimated useful lives of the assets, which range between 3 and 7 years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the terms of the lease. Equipment leased to customers is depreciated over the 3-year estimated useful lives of the related equipment, regardless of whether the equipment is leased to a customer or remaining in stock, and is recorded in cost of revenues for CareServices. Expenditures for maintenance and repairs are expensed as incurred. Upon the sale or disposal of property and equipment, any gains or losses are included in the results of operations. Property and equipment consists of the following as of: | ||||
31-Mar-14 | 30-Sep-13 | |||
Equipment leased to customers | $ 389,492 | $ 389,492 | ||
Equipment | 195,265 | 255,339 | ||
Leasehold improvements | 148,834 | 145,147 | ||
Software | 98,334 | 87,361 | ||
Furniture | 73,886 | 32,855 | ||
Total property and equipment | 905,811 | 910,194 | ||
Accumulated depreciation and amortization | (387,363) | (339,834) | ||
Property and equipment, net | $ 518,448 | $ 570,360 | ||
Depreciation and amortization expense for the six months ended March 31, 2014 and 2013 was $105,842 and $131,913, respectively. | ||||
9_Accrued_Expenses
9. Accrued Expenses | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
9. Accrued Expenses | ' | |||
9. Accrued Expenses | ||||
Accrued expenses consist of the following as of: | ||||
31-Mar-14 | 30-Sep-13 | |||
Warranty reserve | $ 1,400,000 | $ - | ||
Commissions | 503,640 | 527,977 | ||
Payroll expense | 430,727 | 272,451 | ||
Liability to issue common stock | 230,293 | - | ||
Freight and shipping | 176,883 | 123,801 | ||
Deferred rent | 91,027 | 55,242 | ||
Interest | 37,140 | 211,722 | ||
Other | 58,032 | 76,008 | ||
Total accrued liabilities | $ 2,927,742 | $ 1,267,201 |
10_Notes_Payable
10. Notes Payable | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
10. Notes Payable | ' | |||
10. Notes Payable | ||||
The Company had the following notes payable outstanding as of: | ||||
March 31, 2014 | September 30, 2013 | |||
Note payable to the former owners of Green Wire, secured by customer contracts, imputed interest rate of 12%, monthly installments over a 38-month term. In March 2013, the Company issued 15,000 shares of common stock (fair value of $24,000) to extend the term of the note. The fair value is being amortized to interest expense over the remaining life of the note. | $ 1,414,274 | $ 1,766,971 | ||
Unsecured note payable with no interest, due March 2015. The Company issued warrants to purchase 450,000 shares of common stock (fair value of $143,634). The note also requires a payment of 667,000 shares of common stock at the end of the term (fair value of $230,293), recorded as an accrued liability. | 350,000 | - | ||
Unsecured notes with interest at 15% (18% after due date), due April 2013. The Company issued 20,000 shares of Series D preferred stock as loan origination fees (fair value of $195,000). Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. | 64,261 | 185,476 | ||
Notes payable with interest at 12%, secured by the Company's assets, due August 2014. The Company issued warrants to purchase 36,667 shares of common stock (fair value of $51,452) as due diligence fees and issued 25,000 shares of common stock (fair value of $31,250) to a related party as consideration for a personal guarantee. The notes and accrued interest were converted to Series F preferred stock in December 2013. | - | 550,000 | ||
Unsecured note with interest at 12%, due March 2013. The note and accrued interest were converted to common stock in November 2013. | - | 250,000 | ||
March 31, 2014 | September 30, 2013 | |||
Series A debenture loan payable with interest at 12%, secured by customer contracts, payable in monthly installments, and due February 2016. The debenture was converted to Series E preferred stock in October 2013. | $ - | $ 85,719 | ||
Unsecured note with interest at 15%, due March 2013. The note and accrued interest were converted to common stock in November 2013. | - | 25,000 | ||
Total notes payable before discount | 1,828,535 | 2,863,166 | ||
Less discount | (259,966) | (528,663) | ||
Total notes payable | 1,568,569 | 2,334,503 | ||
Less current portion | (932,148) | (1,278,585) | ||
Notes payable, net of current portion | $ 636,421 | $ 1,055,918 | ||
11_Relatedparty_Notes_Payable
11. Related-party Notes Payable | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
11. Related-party Notes Payable | ' | |||
11. Related-Party Notes Payable | ||||
The Company had the following related-party notes payable outstanding as of: | ||||
31-Mar-14 | 30-Sep-13 | |||
Unsecured note payable to an officer of the Company with interest at 15%, due June 2012, currently in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $0.50 per share. | $ 30,000 | $ 33,000 | ||
Unsecured note payable to an officer of the Company with interest at 12%, due September 2013, currently in default, and convertible into common stock at $0.75 per share. | 26,721 | 26,721 | ||
Unsecured note payable to an entity controlled by the Company’s CEO, interest at 12%, due on demand, and convertible into common stock at $0.75 per share. The Company issued 17,500 shares of common stock (fair value of $26,250) as loan origination fees. In December 2013, $160,000 of the note was converted to common stock. | 15,000 | 175,000 | ||
Unsecured note payable to an officer of the Company with interest at 12%, due on demand. | 13,644 | 13,644 | ||
Unsecured notes payable to an entity controlled by an officer of the Company with interest at 15%, due September 2013. The Company issued 60,000 shares of common stock (fair value of $93,000) as loan origination fees. The notes and accrued interest were converted to common stock in December 2013. | - | 600,000 | ||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due September 2013. The Company issued 30,000 shares of common stock (fair value of $38,100) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | - | 300,000 | ||
31-Mar-14 | 30-Sep-13 | |||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due September 2013. The Company issued 30,000 shares of common stock (fair value of $37,500) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | $ - | $ 300,000 | ||
Unsecured notes payable to an entity controlled by an officer of the Company with interest at 12%, due April 2013. The note and accrued interest were converted to common stock in December 2013. | - | 200,000 | ||
Unsecured note payable with no interest to an entity controlled by an officer of the Company, repaid during the three months ended December 31, 2013. | - | 150,000 | ||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due June 2013. The Company issued 5,600 shares of Series D preferred stock (fair value of $56,252) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | - | 82,500 | ||
Unsecured notes payable with no interest to an individual related to an officer of the Company; repaid during the three months ended December 31, 2013. | - | 10,000 | ||
Series B unsecured debenture to an entity controlled by an officer of the Company with interest at 12%, due December 2015. The debenture and accrued interest were converted to common stock during the three months ended December 31, 2013. | - | 5,270 | ||
Total notes payable, related-party, before discount | 85,365 | 1,896,135 | ||
Less discount | - | (3,720) | ||
Total notes payable, related-party | $ 85,365 | $ 1,892,415 |
12_Fair_Value_Measurements
12. Fair Value Measurements | 6 Months Ended | |
Mar. 31, 2014 | ||
Notes | ' | |
12. Fair Value Measurements | ' | |
12. Fair Value Measurements | ||
The Company measured the fair values of its assets and liabilities using the US GAAP hierarchy levels as follows: | ||
Level 1 | The Company does not have any Level 1 inputs available to measure its assets. | |
Level 2 | The Company’s embedded derivative liabilities are measured on a recurring basis using Level 2 inputs. | |
Level 3 | The Company’s goodwill is measured using Level 3 inputs. | |
The Company’s embedded derivative liabilities are re-measured to fair value as of each reporting date until the contingency is resolved, see Note 13. |
13_Derivatives_Liability
13. Derivatives Liability | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
13. Derivatives Liability | ' |
13. Derivatives Liability | |
The derivatives liability as of March 31, 2014 and September 30, 2013 was $0 and $795,151, respectively. The elimination of the derivatives liability was due to the conversion of notes payable with variable conversion features. During the three and six months ended March 31, 2014, the Company estimated the fair value of the embedded derivatives prior to their conversion and elimination using a binomial option-pricing model with the following assumptions, according to the instrument: exercise price of $0.75 per share; risk free interest rate of 0.10%; expected life of 0.63 years; expected dividends of 0%; a volatility factor of 108%; and a stock price of $1.00. The expected lives of the instruments were equal to the average term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option. The gain on derivative liabilities for the six months ended March 31, 2014 and 2013 was $479,737 and $45,697, respectively. |
14_Preferred_Stock
14. Preferred Stock | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
14. Preferred Stock | ' |
14. Preferred Stock | |
The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.00001 per share. Pursuant to the Company’s Certificate of Incorporation, the Board of Directors has the authority to amend the Company’s Certificate of Incorporation without further stockholder approval, to designate and determine the preferences, limitations and relative rights of the preferred stock before any issuance of the preferred stock and to create one or more series of preferred stock, fix the number of shares of each such series, and determine the preferences, limitations and relative rights of each series of preferred stock, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, and liquidation preferences. | |
Series C Convertible Preferred Stock | |
As of September 30, 2013, the Company had 480,000 shares of Series C convertible preferred stock issued and outstanding (“Series C preferred stock”). In December 2013, all 480,000 shares of Series C preferred stock were converted to 672,000 shares of common stock. The conversion rate of 1.4 shares of common stock was greater than the designated conversion rate of one share of common stock and, therefore, the additional 192,000 shares were recorded as a deemed dividend. In addition, the Company recognized $11,367 of dividends on Series C preferred stock and settled the accrued dividends by issuing 11,599 shares of common stock. The Series C preferred stock was non-voting. | |
Series D Convertible Preferred Stock | |
The Board of Directors has designated 1,000,000 shares of preferred stock as Series D convertible preferred stock (“Series D preferred stock”). The Series D preferred stock is voting on an as-converted basis. The Series D preferred stock has a dividend rate of 8%, payable quarterly. The Company may redeem the Series D preferred shares at a redemption price equal to 120% of the original purchase price with 15 days notice. In December 2013, 893,218 shares of Series D preferred stock were converted to 6,252,526 shares of common stock. The conversion rate of 7 shares of common stock was greater than the designated conversion rate of 5 shares of common stock and, therefore, the additional 1,786,436 shares were recorded as a deemed dividend. In addition, the Company recognized $50,764 of dividends on Series D preferred stock and settled the accrued dividends by issuing 54,738 shares of common stock. | |
Series E Convertible Preferred Stock | |
During fiscal year 2013, the Board of Directors designated shares of preferred stock as Series E convertible preferred stock (“Series E preferred stock”). Series E preferred stock is convertible into common stock at $1.00 per share, the conversion price is adjustable if there are distributions of common stock or a stock split by the Company. The designation also provides that the Series E preferred stock is non-voting and receives a monthly dividend of 3.322% for 25 to 32 months. In addition, the convertibility and the redemption price of the Series E preferred stock is gradually reduced by dividend payments over 25 to 32 months. After the dividend payment term, the redemption price of Series E preferred stock is $0 and the Series E preferred stock has no convertibility to common stock. During the three months ended December 31, 2013, the Company issued 8,347 shares of Series E preferred stock for the conversion of an $83,473 note payable and accrued interest. | |
During the three and six months ended March 31, 2014, the Company paid dividends of $81,716 and $156,639, respectively, to Series E preferred stockholders. As of March 31, 2014, the redemption price for the Series E preferred stock was $559,737. | |
Series F Convertible Preferred Stock | |
During the three months ended December 31, 2013, the Board of Directors designated 7,803 shares of preferred stock as Series F convertible preferred stock (“Series F preferred stock”). Series F preferred stock is non-voting, has a stated value of $1,000 and is convertible into common stock at $1.00 per share. The Series F preferred stock has a dividend rate, payable quarterly, of 8% until April 30, 2015, 16% from May 1, 2015 to July 31, 2015, 20% from August 1, 2015 to October 31, 2015 and 25% thereafter. | |
During the three months ended March 31, 2014, the Company issued 1,008 shares of Series F preferred stock for net proceeds of $810,000, after considering $198,000 of related costs. During the six months ended March 31, 2014, the Company issued 5,361 shares of Series F preferred stock for net proceeds of $3,580,771, after considering $675,229 of related costs, and the conversion of $574,592 of debt and accrued interest. | |
Liquidation Preference | |
Upon any liquidation, dissolution or winding up of the Company, before any distribution or payment may be made to the holders of the common stock, the holders of the Series C preferred stock, Series D preferred stock, Series E preferred stock, and Series F preferred stock are entitled to be paid out of the assets an amount equal to $1.00 per share plus all accrued but unpaid dividends. If the assets of the Company are insufficient to make payment in full to all holders of preferred stock, then the assets shall be distributed among the holders of preferred stock ratably in proportion to the full amounts to which they would otherwise be respectively entitled. |
15_Common_Stock
15. Common Stock | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
15. Common Stock | ' |
15. Common Stock | |
During the six months ended March 31, 2014, the Company issued 12,558,764 shares of common stock as follows: | |
· 3,712,549 shares to settle notes payable and related accrued interest, the value on the date of grant was $2,447,857; | |
· 584,100 shares to the Chief Executive Officer for the exercise of a modified stock option agreement (the exercise price was reduced to $0), the change in value due to the modification was $134,897; | |
· 474,000 shares to a former Chief Executive Officer for the exercise of a modified stock option agreement (the exercise price was reduced to $0), the change in value due to the modification was $400,585; | |
· 161,738 shares for notes payable origination fees, the value on the date of grant was $163,170; | |
· 125,000 shares for services provided by independent consultants, the value on the date of grant was $110,000; | |
· 60,000 shares for employee bonuses, the value on the date of grant was $52,200; | |
· 100,000 shares for services provided by a board member, the value on the date of grant was $85,000; | |
· 342,930 shares for equity investment finders’ fees, the value on the date of grant was $342,000; | |
· 6,924,526 shares in connection with the conversion of 480,000 shares of Series C preferred stock and 893,218 shares of Series D preferred stock; | |
· 73,921 shares to settle accrued dividends for Series C preferred stock and Series D preferred stock, the value on the date of grant was $68,245. | |
16_Stock_Options_and_Warrants
16 Stock Options and Warrants | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
16 Stock Options and Warrants | ' | |||
16. Common Stock Options and Warrants | ||||
The fair value of common stock options and warrants are estimated on the dates of grant using a binomial option-pricing model. The expected lives of stock options and warrants represent the period of time that the stock options and warrants are expected to be outstanding, based on the simplified method. Expected volatilities are based on historical volatility of the Company’s common stock, among other factors. The Company uses the simplified method within the valuation model due to the Company’s short trading history and limited exercise history. The risk-free rate related to the expected term of the stock option and warrants is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is zero. | ||||
During fiscal years 2014 and 2013, the Company measured the fair values of the warrants using a binomial valuation model with the following assumptions: | ||||
Six Months Ended | ||||
March 31, | ||||
2014 | 2013 | |||
Exercise price | $0.95 - $1.10 | $1.00 - $1.50 | ||
Expected term (years) | 3-Feb | 2.5 - 5 | ||
Volatility | 213% - 216% | 223% - 298% | ||
Risk-free rate | 0.28% - 0.71% | 0.35% - 0.88% | ||
Dividend rate | 0% | 0% | ||
During the six months ended March 31, 2014, the Company granted the following common stock options and warrants: | ||||
· Options to purchase 650,000 shares were granted to an entity controlled by an officer of the Company for notes payable and accrued interest converted into common stock, with an exercise price of $1.10 per share. The options expire in December 2018. The Company recognized $590,887 of interest expense during the three months ended December 31, 2013; | ||||
· Options to purchase 450,000 shares were granted to a note holder with an exercise price of $1.00 per share. The options expire in October 2018. The Company recognized $143,634 as debt discount, which is being amortized over the life of the note payable; | ||||
· Options to purchase 856,977 shares were granted to two note holders for converting debt into common stock with an exercise price of $1.10 per share. The options expire in December 2018; | ||||
· Options to purchase 3,669,120 shares were granted in connection with the sale of Series F preferred stock with an exercise price of $1.10 per share. The options expire in December 2018; | ||||
· Options to purchase 1,424,025 shares were granted in connection with the sale of Series F preferred stock with an exercise price of $1.10 per share. The options expire in January 2018; | ||||
· Options to purchase 1,008,000 shares were granted in connection with the sale of Series F preferred stock with an exercise price of $1.10 per share. The options expire in February 2019. | ||||
The following table summarizes information about common stock options and warrants outstanding as of March 31, 2014: | ||||
Options and Warrants | Number of Options and Warrants | Weighted-Average Exercise Price | ||
Outstanding as of October 1, 2013 | 3,598,554 | $ 1.33 | ||
Granted | 8,058,122 | 1.09 | ||
Exercised | (1,058,100) | 1.00 | ||
Forfeited | - | - | ||
Outstanding as of March 31, 2014 | 10,598,576 | 1.18 | ||
Exercisable as of March 31, 2014 | 9,568,576 | 1.19 | ||
As of March 31, 2014, the outstanding warrants have an aggregate intrinsic value of $0, and the weighted average remaining term of the warrants is 4.3 years. |
17_Segment_Information
17. Segment Information | 6 Months Ended | |||||
Mar. 31, 2014 | ||||||
Notes | ' | |||||
17. Segment Information | ' | |||||
17. Segment Information | ||||||
The Company operates two business segments based primarily on the nature of the Company’s products. The Chronic Illness Monitoring segment is engaged in the business of developing, distributing and marketing mobile monitoring of patient vital signs and physical activity to self-insured companies, insurance companies, and disease management companies. The CareServices segment is engaged in the business of developing, distributing and marketing mobile health monitoring and concierge services to distributors and consumers. The Company previously operated a reagents business which was sold in June 2013. The Company no longer holds any ownership interest in the reagents business. | ||||||
At the corporate level, the Company raises capital and provides for the administrative operations of the Company as a whole. | ||||||
The following table reflects certain financial information relating to each reportable segment as of March 31, 2014 and 2013 and for the three months then ended: | ||||||
Corporate | Chronic Illness Monitoring | CareServices | Reagents | Total | ||
Three months ended March 31, 2014 | ||||||
Revenues | $ - | $ 814,187 | $ 276,764 | $ - | $ 1,090,951 | |
Net loss | (2,382,809) | (1,867,630) | (245,631) | - | (4,496,070) | |
Interest expense, net | 171,422 | - | - | - | 171,422 | |
Total assets | 628,370 | 8,309,224 | 1,818,221 | - | 10,755,815 | |
Property and equipment purchases | 7,057 | - | - | - | 7,057 | |
Depreciation and amortization | 26,259 | 28,610 | 235,700 | - | 290,569 | |
Three months ended March 31, 2013 | ||||||
Revenues | $ - | $ 4,256,011 | $ 457,113 | $ 130,029 | $ 4,843,153 | |
Net income (loss) | (2,011,486) | 455,392 | (914,966) | 20,731 | (2,450,329) | |
Interest expense, net | 767,391 | - | - | - | 767,391 | |
Total assets | 20,816 | 7,517,626 | 3,255,691 | 161,064 | 10,955,197 | |
Property and equipment purchases | - | - | 132,993 | 888 | 133,881 | |
Depreciation and amortization | 179 | 28,610 | 278,557 | 3,211 | 310,557 | |
The following table reflects certain financial information relating to each reportable segment as of March 31, 2014 and 2013 and for the six months then ended: | ||||||
Corporate | Chronic Illness Monitoring | CareServices | Reagents | Total | ||
Six months ended March 31, 2014 | ||||||
Revenues | $ - | $ 2,893,654 | $ 625,555 | $ - | $ 3,519,209 | |
Net loss | (5,179,511) | (1,519,988) | (548,413) | - | (7,247,912) | |
Interest expense, net | 1,440,498 | - | - | - | 1,440,498 | |
Total assets | 628,370 | 8,309,224 | 1,818,221 | - | 10,755,815 | |
Property and equipment purchases | 58,145 | - | - | - | 58,145 | |
Depreciation and amortization | 56,092 | 57,220 | 472,839 | - | 586,151 | |
Six months ended March 31, 2013 | ||||||
Revenues | $ - | $ 6,209,615 | $ 876,801 | $ 254,499 | $ 7,340,915 | |
Net income (loss) | (4,302,830) | 224,157 | (1,958,743) | 6,370 | (6,031,046) | |
Interest expense, net | 1,790,983 | - | - | - | 1,790,983 | |
Total assets | 20,816 | 7,517,626 | 3,255,691 | 161,064 | 10,955,197 | |
Property and equipment purchases | - | - | 266,522 | 888 | 267,410 | |
Depreciation and amortization | 357 | 57,220 | 548,190 | 6,451 | 612,218 | |
18_Commitments_and_Contingenci
18. Commitments and Contingencies | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Notes | ' | |||
18. Commitments and Contingencies | ' | |||
18. Commitments and Contingencies | ||||
The Company leases office space under non-cancelable operating leases. Future minimum rental payments under non-cancelable operating leases are as follows: | ||||
Years Ending September 30, | ||||
2014 | $ 152,539 | |||
2015 | 308,330 | |||
2016 | 317,580 | |||
2017 | 327,107 | |||
2018 | 280,077 | |||
$ 1,385,633 | ||||
The Company’s rent expense for facilities held under non-cancelable operating leases for the six months ended March 31, 2014 and 2013 was approximately $150,000 and $107,000, respectively. | ||||
In May 2013, the Company entered into a settlement agreement and patent license agreement through which all claims of a lawsuit were dismissed. The final payment required by the settlement agreement and patent license agreement was made in December 2013. |
19_Subsequent_Events
19. Subsequent Events | 6 Months Ended |
Mar. 31, 2014 | |
Notes | ' |
19. Subsequent Events | ' |
19. Subsequent Events | |
(1) In April 2014, the Company filed a preliminary information statement to (1) amend the Corporation’s Certificate of Incorporation increasing the total number of authorized shares of common stock from 50,000,000 shares to 200,000,000 shares; and (2) amend the Series F preferred stock designation to increase the authorized shares of Series F preferred stock from 7,803 to 10,000. | |
(2) In April 2014, James Carter resigned as a member of the Board of Directors of the Company. There were no disagreements between Mr. Carter and the Company or any officer or director of the Company which led to Mr. Carter’s resignation. In May 2014, the Board of Directors appointed Jeffery Peterson to fill the vacancy on the Board of Directors created by Mr. Carter’s resignation. | |
(3) In April 2014, the Board of Directors appointed Michael Jones as President of the Company and Jonathan Olson as Chief Operating Officer of the Company. | |
(4) In April and May 2014, the Company received advances totaling $225,000 from the Company’s Chief Executive Officer. | |
(5) In April 2014, the Company issued 90,000 warrants to purchase shares of common stock for $1.10 to third parties for services. | |
1_Organization_and_Nature_of_O1
1. Organization and Nature of Operations: Going Concern (Policies) | 6 Months Ended |
Mar. 31, 2014 | |
Policies | ' |
Going Concern | ' |
Going Concern | |
The Company continues to incur negative cash flows from operating activities and recurring net losses. The Company had negative working capital as of March 31, 2014 and September 30, 2013. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | |
In order for the Company to eliminate substantial doubt about its ability to continue as a going concern, it must improve gross margins, generate positive cash flows from operating activities and obtain the necessary debt or equity funding to meet its projected capital investment requirements. Management’s plans with respect to this uncertainty include raising additional capital by issuing debt or equity securities and increasing the sales of the Company’s services and products. During the six months ended March 31, 2014, the Company (1) completed the sale of Series F convertible preferred stock (“Series F preferred stock”) for net proceeds of $3,580,771, after considering $675,229 of related costs; (2) converted $2,326,801 of debt and accrued interest to common stock; (3) converted $574,592 of debt and accrued interest to Series F preferred stock; and (4) converted $83,473 of debt and accrued interest to Series E preferred stock. There can be no assurance that the Company will be able to raise sufficient additional capital or that revenues will increase rapidly enough to offset operating losses. If the Company is unable to increase revenues or obtain additional financing, it will be unable to continue the development of its products and may have to cease operations. |
1_Organization_and_Nature_of_O2
1. Organization and Nature of Operations: Use of Estimates in The Preparation of Financial Statements (Policies) | 6 Months Ended |
Mar. 31, 2014 | |
Policies | ' |
Use of Estimates in The Preparation of Financial Statements | ' |
Use of Estimates in the Preparation of Financial Statements | |
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the balance sheet dates and the reported amounts of revenues and expenses for the reporting periods. Actual results could differ from these estimates. |
1_Organization_and_Nature_of_O3
1. Organization and Nature of Operations: Fair Value of Financial Instruments (Policies) | 6 Months Ended |
Mar. 31, 2014 | |
Policies | ' |
Fair Value of Financial Instruments | ' |
Fair Value of Financial Instruments | |
The Company measured the fair values of its assets and liabilities using the US GAAP hierarchy. The carrying amounts reported in the condensed consolidated balance sheets for cash, accounts receivable, accounts payable, and accrued liabilities approximate fair values due to the short-term nature and liquidity of these financial instruments. Derivative financial instruments are recorded at fair value based on current market pricing models. The carrying amounts reported for notes payable approximate fair value because the underlying instruments are at interest rates which approximate current market rates. |
2_Discontinued_Operations_Sche
2. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures | ' | |||
Three months ended | Six months ended | |||
31-Mar-13 | 31-Mar-13 | |||
Revenues | $ 130,029 | $ 254,499 | ||
Cost of revenues | (71,739) | (169,599) | ||
Gross margin | 58,290 | 84,900 | ||
Selling, general and administrative expense | (37,559) | (78,530) | ||
Gain from discontinued operations | $ 20,731 | $ 6,370 |
3_EarningsPerShareTextBlock_Sc
3. EarningsPerShareTextBlock: Schedule of Common Stock Equivalents (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Common Stock Equivalents | ' | |||
31-Mar-14 | 31-Mar-13 | |||
Common stock options and warrants | 10,598,576 | 4,136,887 | ||
Series C convertible preferred stock | - | 480,000 | ||
Series D convertible preferred stock | 225,000 | 4,207,715 | ||
Series E convertible preferred stock | 559,737 | - | ||
Series F convertible preferred stock | 5,361,000 | - | ||
Convertible debt | 80,000 | 822,250 | ||
Restricted shares of common stock | 17,250 | 40,200 | ||
Total common stock equivalents | 16,841,563 | 9,687,052 | ||
6_Customer_Contracts_Disclosur1
6. Customer Contracts Disclosure: Schedule of Future Customer Contract Amortization (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Future Customer Contract Amortization | ' | |||
Years Ending September 30, | ||||
2014 | $ 359,296 | |||
2015 | 658,709 | |||
$ 1,018,005 |
7_Patents_Schedule_of_FiniteLi
7. Patents: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables) | 6 Months Ended | ||||
Mar. 31, 2014 | |||||
Tables/Schedules | ' | ||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | ' | ||||
Years Ending September 30, | |||||
2014 | $ 63,435 | ||||
2015 | 126,870 | ||||
2016 | 126,870 | ||||
2017 | 126,870 | ||||
2018 | 59,440 | ||||
$ 503,485 | |||||
8_Property_and_Equipment_Prope
8. Property and Equipment: Property, Plant and Equipment (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Property, Plant and Equipment | ' | |||
31-Mar-14 | 30-Sep-13 | |||
Equipment leased to customers | $ 389,492 | $ 389,492 | ||
Equipment | 195,265 | 255,339 | ||
Leasehold improvements | 148,834 | 145,147 | ||
Software | 98,334 | 87,361 | ||
Furniture | 73,886 | 32,855 | ||
Total property and equipment | 905,811 | 910,194 | ||
Accumulated depreciation and amortization | (387,363) | (339,834) | ||
Property and equipment, net | $ 518,448 | $ 570,360 |
9_Accrued_Expenses_Schedule_of
9. Accrued Expenses: Schedule of Accrued Expenses (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Accrued Expenses | ' | |||
Accrued expenses consist of the following as of: | ||||
31-Mar-14 | 30-Sep-13 | |||
Warranty reserve | $ 1,400,000 | $ - | ||
Commissions | 503,640 | 527,977 | ||
Payroll expense | 430,727 | 272,451 | ||
Liability to issue common stock | 230,293 | - | ||
Freight and shipping | 176,883 | 123,801 | ||
Deferred rent | 91,027 | 55,242 | ||
Interest | 37,140 | 211,722 | ||
Other | 58,032 | 76,008 | ||
Total accrued liabilities | $ 2,927,742 | $ 1,267,201 |
10_Notes_Payable_Schedule_of_D
10. Notes Payable: Schedule of Debt - Other (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Debt - Other | ' | |||
March 31, 2014 | September 30, 2013 | |||
Note payable to the former owners of Green Wire, secured by customer contracts, imputed interest rate of 12%, monthly installments over a 38-month term. In March 2013, the Company issued 15,000 shares of common stock (fair value of $24,000) to extend the term of the note. The fair value is being amortized to interest expense over the remaining life of the note. | $ 1,414,274 | $ 1,766,971 | ||
Unsecured note payable with no interest, due March 2015. The Company issued warrants to purchase 450,000 shares of common stock (fair value of $143,634). The note also requires a payment of 667,000 shares of common stock at the end of the term (fair value of $230,293), recorded as an accrued liability. | 350,000 | - | ||
Unsecured notes with interest at 15% (18% after due date), due April 2013. The Company issued 20,000 shares of Series D preferred stock as loan origination fees (fair value of $195,000). Principal of $50,000 and accrued interest of $13,333 were converted to common stock in December 2013. | 64,261 | 185,476 | ||
Notes payable with interest at 12%, secured by the Company's assets, due August 2014. The Company issued warrants to purchase 36,667 shares of common stock (fair value of $51,452) as due diligence fees and issued 25,000 shares of common stock (fair value of $31,250) to a related party as consideration for a personal guarantee. The notes and accrued interest were converted to Series F preferred stock in December 2013. | - | 550,000 | ||
Unsecured note with interest at 12%, due March 2013. The note and accrued interest were converted to common stock in November 2013. | - | 250,000 | ||
March 31, 2014 | September 30, 2013 | |||
Series A debenture loan payable with interest at 12%, secured by customer contracts, payable in monthly installments, and due February 2016. The debenture was converted to Series E preferred stock in October 2013. | $ - | $ 85,719 | ||
Unsecured note with interest at 15%, due March 2013. The note and accrued interest were converted to common stock in November 2013. | - | 25,000 | ||
Total notes payable before discount | 1,828,535 | 2,863,166 | ||
Less discount | (259,966) | (528,663) | ||
Total notes payable | 1,568,569 | 2,334,503 | ||
Less current portion | (932,148) | (1,278,585) | ||
Notes payable, net of current portion | $ 636,421 | $ 1,055,918 | ||
11_Relatedparty_Notes_Payable_
11. Related-party Notes Payable: Schedule of Related Party Transactions (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Related Party Transactions | ' | |||
31-Mar-14 | 30-Sep-13 | |||
Unsecured note payable to an officer of the Company with interest at 15%, due June 2012, currently in default. The note included a $3,000 loan origination fee added to the principal and is convertible into common stock at $0.50 per share. | $ 30,000 | $ 33,000 | ||
Unsecured note payable to an officer of the Company with interest at 12%, due September 2013, currently in default, and convertible into common stock at $0.75 per share. | 26,721 | 26,721 | ||
Unsecured note payable to an entity controlled by the Company’s CEO, interest at 12%, due on demand, and convertible into common stock at $0.75 per share. The Company issued 17,500 shares of common stock (fair value of $26,250) as loan origination fees. In December 2013, $160,000 of the note was converted to common stock. | 15,000 | 175,000 | ||
Unsecured note payable to an officer of the Company with interest at 12%, due on demand. | 13,644 | 13,644 | ||
Unsecured notes payable to an entity controlled by an officer of the Company with interest at 15%, due September 2013. The Company issued 60,000 shares of common stock (fair value of $93,000) as loan origination fees. The notes and accrued interest were converted to common stock in December 2013. | - | 600,000 | ||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due September 2013. The Company issued 30,000 shares of common stock (fair value of $38,100) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | - | 300,000 | ||
31-Mar-14 | 30-Sep-13 | |||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due September 2013. The Company issued 30,000 shares of common stock (fair value of $37,500) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | $ - | $ 300,000 | ||
Unsecured notes payable to an entity controlled by an officer of the Company with interest at 12%, due April 2013. The note and accrued interest were converted to common stock in December 2013. | - | 200,000 | ||
Unsecured note payable with no interest to an entity controlled by an officer of the Company, repaid during the three months ended December 31, 2013. | - | 150,000 | ||
Unsecured note payable to an entity controlled by an officer of the Company with interest at 12%, due June 2013. The Company issued 5,600 shares of Series D preferred stock (fair value of $56,252) as loan origination fees. The note and accrued interest were converted to common stock in December 2013. | - | 82,500 | ||
Unsecured notes payable with no interest to an individual related to an officer of the Company; repaid during the three months ended December 31, 2013. | - | 10,000 | ||
Series B unsecured debenture to an entity controlled by an officer of the Company with interest at 12%, due December 2015. The debenture and accrued interest were converted to common stock during the three months ended December 31, 2013. | - | 5,270 | ||
Total notes payable, related-party, before discount | 85,365 | 1,896,135 | ||
Less discount | - | (3,720) | ||
Total notes payable, related-party | $ 85,365 | $ 1,892,415 |
16_Stock_Options_and_Warrants_
16 Stock Options and Warrants: Schedule of Warrants Fair Value Assumptions (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Warrants Fair Value Assumptions | ' | |||
Six Months Ended | ||||
March 31, | ||||
2014 | 2013 | |||
Exercise price | $0.95 - $1.10 | $1.00 - $1.50 | ||
Expected term (years) | 3-Feb | 2.5 - 5 | ||
Volatility | 213% - 216% | 223% - 298% | ||
Risk-free rate | 0.28% - 0.71% | 0.35% - 0.88% | ||
Dividend rate | 0% | 0% | ||
16_Stock_Options_and_Warrants_1
16 Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Share-based Compensation, Activity | ' | |||
Options and Warrants | Number of Options and Warrants | Weighted-Average Exercise Price | ||
Outstanding as of October 1, 2013 | 3,598,554 | $ 1.33 | ||
Granted | 8,058,122 | 1.09 | ||
Exercised | (1,058,100) | 1.00 | ||
Forfeited | - | - | ||
Outstanding as of March 31, 2014 | 10,598,576 | 1.18 | ||
Exercisable as of March 31, 2014 | 9,568,576 | 1.19 | ||
17_Segment_Information_Schedul
17. Segment Information: Schedule of Segment Reporting Information, by Segment (Tables) | 6 Months Ended | |||||
Mar. 31, 2014 | ||||||
Tables/Schedules | ' | |||||
Schedule of Segment Reporting Information, by Segment | ' | |||||
Corporate | Chronic Illness Monitoring | CareServices | Reagents | Total | ||
Three months ended March 31, 2014 | ||||||
Revenues | $ - | $ 814,187 | $ 276,764 | $ - | $ 1,090,951 | |
Net loss | (2,382,809) | (1,867,630) | (245,631) | - | (4,496,070) | |
Interest expense, net | 171,422 | - | - | - | 171,422 | |
Total assets | 628,370 | 8,309,224 | 1,818,221 | - | 10,755,815 | |
Property and equipment purchases | 7,057 | - | - | - | 7,057 | |
Depreciation and amortization | 26,259 | 28,610 | 235,700 | - | 290,569 | |
Three months ended March 31, 2013 | ||||||
Revenues | $ - | $ 4,256,011 | $ 457,113 | $ 130,029 | $ 4,843,153 | |
Net income (loss) | (2,011,486) | 455,392 | (914,966) | 20,731 | (2,450,329) | |
Interest expense, net | 767,391 | - | - | - | 767,391 | |
Total assets | 20,816 | 7,517,626 | 3,255,691 | 161,064 | 10,955,197 | |
Property and equipment purchases | - | - | 132,993 | 888 | 133,881 | |
Depreciation and amortization | 179 | 28,610 | 278,557 | 3,211 | 310,557 | |
The following table reflects certain financial information relating to each reportable segment as of March 31, 2014 and 2013 and for the six months then ended: | ||||||
Corporate | Chronic Illness Monitoring | CareServices | Reagents | Total | ||
Six months ended March 31, 2014 | ||||||
Revenues | $ - | $ 2,893,654 | $ 625,555 | $ - | $ 3,519,209 | |
Net loss | (5,179,511) | (1,519,988) | (548,413) | - | (7,247,912) | |
Interest expense, net | 1,440,498 | - | - | - | 1,440,498 | |
Total assets | 628,370 | 8,309,224 | 1,818,221 | - | 10,755,815 | |
Property and equipment purchases | 58,145 | - | - | - | 58,145 | |
Depreciation and amortization | 56,092 | 57,220 | 472,839 | - | 586,151 | |
Six months ended March 31, 2013 | ||||||
Revenues | $ - | $ 6,209,615 | $ 876,801 | $ 254,499 | $ 7,340,915 | |
Net income (loss) | (4,302,830) | 224,157 | (1,958,743) | 6,370 | (6,031,046) | |
Interest expense, net | 1,790,983 | - | - | - | 1,790,983 | |
Total assets | 20,816 | 7,517,626 | 3,255,691 | 161,064 | 10,955,197 | |
Property and equipment purchases | - | - | 266,522 | 888 | 267,410 | |
Depreciation and amortization | 357 | 57,220 | 548,190 | 6,451 | 612,218 | |
18_Commitments_and_Contingenci1
18. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Tables) | 6 Months Ended | |||
Mar. 31, 2014 | ||||
Tables/Schedules | ' | |||
Schedule of Future Minimum Rental Payments for Operating Leases | ' | |||
Years Ending September 30, | ||||
2014 | $ 152,539 | |||
2015 | 308,330 | |||
2016 | 317,580 | |||
2017 | 327,107 | |||
2018 | 280,077 | |||
$ 1,385,633 |
1_Organization_and_Nature_of_O4
1. Organization and Nature of Operations (Details) | 6 Months Ended |
Mar. 31, 2014 | |
Details | ' |
Stockholders' Equity, Reverse Stock Split | 'During fiscal year 2013, the Company completed a 10-for-1 reverse common stock split, and all periods presented have been retroactively adjusted to reflect the reverse common stock split. |
2_Discontinued_Operations_Sche1
2. Discontinued Operations: Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures (Details) (USD $) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | |
Gross profit (deficit) | ($1,425,250) | $843,390 | ($491,031) | $1,033,369 |
Selling, general and administrative (including $1,002,196, $73,783, $1,574,390, and $1,502,502, respectively, of stock-based compensation) | 2,885,504 | 2,300,860 | 5,595,205 | 4,872,224 |
Gain from discontinued operations | ' | 20,731 | 0 | 6,370 |
Segment, Discontinued Operations | ' | ' | ' | ' |
Revenues | 130,029 | ' | 254,499 | ' |
Cost of Revenue | -71,739 | ' | -169,599 | ' |
Gross profit (deficit) | 58,290 | ' | 84,900 | ' |
Selling, general and administrative (including $1,002,196, $73,783, $1,574,390, and $1,502,502, respectively, of stock-based compensation) | -37,559 | ' | -78,530 | ' |
Gain from discontinued operations | $20,731 | ' | $6,370 | ' |
3_EarningsPerShareTextBlock_Sc1
3. EarningsPerShareTextBlock: Schedule of Common Stock Equivalents (Details) | Mar. 31, 2014 | Mar. 31, 2013 |
Details | ' | ' |
Exercise of outstanding common stock options and warrants | 10,598,576 | 4,136,887 |
Conversion of Series C preferred stock | ' | 480,000 |
Conversion of Series D preferred stock | 225,000 | 4,207,715 |
Conversion of Series E preferred stock | 559,737 | ' |
Conversion of Series F preferred stock | 5,361,000 | ' |
Conversion of debt | 80,000 | 822,250 |
Issuance of employee restricted shares | 17,250 | 40,200 |
Total common stock equivalents | 16,841,563 | 9,687,052 |
5_Inventory_Details
5. Inventory (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Details | ' | ' |
Inventory | $768,940 | $1,249,220 |
6_Customer_Contracts_Disclosur2
6. Customer Contracts Disclosure (Details) (USD $) | 6 Months Ended | 12 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | |
Details | ' | ' | ' | ' |
Customer contracts acquired | ' | ' | $2,369,882 | ' |
Amortization | 416,516 | 416,516 | ' | ' |
Accumulated Amortization of Other Deferred Costs | $1,351,877 | ' | ' | $935,361 |
6_Customer_Contracts_Disclosur3
6. Customer Contracts Disclosure: Schedule of Future Customer Contract Amortization (Details) (USD $) | 6 Months Ended |
Mar. 31, 2014 | |
Details | ' |
Future customer contract amortization year 1 | $359,296 |
Future customer contract amortization year 2 | 658,709 |
Future customer contract amortization | $1,018,005 |
7_Patents_Details
7. Patents (Details) (USD $) | 6 Months Ended | ||
Mar. 31, 2014 | Mar. 31, 2013 | Sep. 30, 2013 | |
Details | ' | ' | ' |
Amortization of Intangible Assets | $63,436 | $63,436 | ' |
Finite-Lived Intangible Assets, Accumulated Amortization | $418,893 | ' | $355,458 |
7_Patents_Schedule_of_FiniteLi1
7. Patents: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Details | ' | ' |
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months | $63,435 | ' |
Finite-Lived Intangible Assets, Amortization Expense, Year Two | 126,870 | ' |
Finite-Lived Intangible Assets, Amortization Expense, Year Three | 126,870 | ' |
Finite-Lived Intangible Assets, Amortization Expense, Year Four | 126,870 | ' |
Finite-Lived Intangible Assets, Amortization Expense, Year Five | 59,440 | ' |
Patents, net | $503,485 | $566,920 |
8_Property_and_Equipment_Prope1
8. Property and Equipment: Property, Plant and Equipment (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Property and equipment, net | $518,448 | $570,360 |
Property, Plant and Equipment, Gross | 905,811 | 910,194 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | -387,363 | -339,834 |
EquipmentLeasedToCustomersMember | ' | ' |
Property and equipment, net | 389,492 | 389,492 |
Equipment | ' | ' |
Property and equipment, net | 195,265 | 255,339 |
Leaseholds and Leasehold Improvements | ' | ' |
Property and equipment, net | 148,834 | 145,147 |
Computer Software, Intangible Asset | ' | ' |
Property and equipment, net | 98,334 | 87,361 |
Furniture and Fixtures | ' | ' |
Property and equipment, net | $73,886 | $32,855 |
8_Property_and_Equipment_Detai
8. Property and Equipment (Details) (USD $) | 6 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Details | ' | ' |
Depreciation, Amortization and Accretion, Net | $105,842 | $131,913 |
9_Accrued_Expenses_Schedule_of1
9. Accrued Expenses: Schedule of Accrued Expenses (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Details | ' | ' |
Accrued warranty reserve | $1,400,000 | ' |
Accrued Sales Commission | 503,640 | 527,977 |
Employee-related Liabilities | 430,727 | 272,451 |
Accrued liability to issue common stock | 230,293 | ' |
Accrued freight and shipping | 176,883 | 123,801 |
Accrued Rent | 91,027 | 55,242 |
Interest Payable | 37,140 | 211,722 |
Other Accrued Liabilities | 58,032 | 76,008 |
Accrued Liabilities | $2,927,742 | $1,267,201 |
10_Notes_Payable_Schedule_of_D1
10. Notes Payable: Schedule of Debt - Other (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Gross notes payable before discount | $1,828,535 | $2,863,166 |
Discount on notes payable | -259,966 | -528,663 |
Notes payable current and noncurrent | 1,568,569 | 2,334,503 |
Current portion of notes payable | -932,148 | -1,278,585 |
Notes payable, net of current portion | 636,421 | 1,055,918 |
Note 1 | ' | ' |
Gross notes payable before discount | 1,414,274 | 1,766,971 |
Note 2 | ' | ' |
Gross notes payable before discount | 350,000 | ' |
Note 3 | ' | ' |
Gross notes payable before discount | 64,261 | 185,476 |
Note 4 | ' | ' |
Gross notes payable before discount | ' | 550,000 |
Note 5 | ' | ' |
Gross notes payable before discount | ' | 250,000 |
Note 6 | ' | ' |
Gross notes payable before discount | ' | 85,719 |
Note 7 | ' | ' |
Gross notes payable before discount | ' | $25,000 |
11_Relatedparty_Notes_Payable_1
11. Related-party Notes Payable: Schedule of Related Party Transactions (Details) (USD $) | Mar. 31, 2014 | Sep. 30, 2013 |
Gross notes payable related party before discount | $85,365 | $1,896,135 |
Discount on notes payable related party | ' | -3,720 |
Notes payable, related-party | 85,365 | 1,892,415 |
RelatedPartyNote1Member | ' | ' |
Gross notes payable related party before discount | 30,000 | 33,000 |
RelatedPartyNote2Member | ' | ' |
Gross notes payable related party before discount | 26,721 | 26,721 |
RelatedPartyNote3Member | ' | ' |
Gross notes payable related party before discount | 15,000 | 175,000 |
RelatedPartyNote4Member | ' | ' |
Gross notes payable related party before discount | 13,644 | 13,644 |
RelatedPartyNote5Member | ' | ' |
Gross notes payable related party before discount | ' | 600,000 |
RelatedPartyNote6Member | ' | ' |
Gross notes payable related party before discount | ' | 300,000 |
RelatedPartyNote7Member | ' | ' |
Gross notes payable related party before discount | ' | 300,000 |
RelatedPartyNote8Member | ' | ' |
Gross notes payable related party before discount | ' | 200,000 |
RelatedPartyNote9Member | ' | ' |
Gross notes payable related party before discount | ' | 150,000 |
RelatedPartyNote10Member | ' | ' |
Gross notes payable related party before discount | ' | 82,500 |
RelatedPartyNote11Member | ' | ' |
Gross notes payable related party before discount | ' | 10,000 |
RelatedPartyNote12Member | ' | ' |
Gross notes payable related party before discount | ' | $5,270 |
13_Derivatives_Liability_Detai
13. Derivatives Liability (Details) (USD $) | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Sep. 30, 2013 | |
Details | ' | ' | ' | ' | ' |
Derivatives liability | $0 | ' | $0 | ' | $795,151 |
Gain on derivatives liability | $0 | $7,360 | $479,737 | $45,697 | ' |
14_Preferred_Stock_Details
14. Preferred Stock (Details) (USD $) | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | |
Series C Preferred Stock | Series C Preferred Stock | Series D Preferred Stock | Series E Preferred Stock | Series E Preferred Stock | Series E Preferred Stock | Series F Preferred Stock | Series F Preferred Stock | Series F Preferred Stock | |||||
Convertible Preferred Stock Shares Designated | ' | ' | ' | ' | 480,000 | ' | 1,000,000 | ' | ' | ' | ' | 7,803 | ' |
Convertible Preferred Stock Shares Issued | ' | ' | ' | ' | ' | 480,000 | ' | ' | 893,218 | ' | 1,008 | ' | 5,361 |
Dividends on preferred stock | ($181,810) | ($74,432) | ($346,833) | ($133,974) | $11,367 | ' | $50,764 | $81,716 | ' | $156,639 | ' | ' | ' |
Stock issued to settle accrued dividends | ' | ' | ' | ' | 11,599 | ' | 54,738 | ' | ' | ' | ' | ' | ' |
Convertible Preferred Stock Shares Deemed Dividend | ' | ' | ' | ' | ' | ' | 1,786,436 | ' | ' | ' | ' | ' | ' |
Preferred Stock, Redemption Amount | ' | ' | ' | ' | ' | ' | ' | 559,737 | ' | 559,737 | ' | ' | ' |
Proceeds from Issuance of Preferred Stock and Preference Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 810,000 | ' | 3,580,771 |
Costs Related to Issuance of Preferred Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 198,000 | ' | 675,229 |
Conversion of debt and accrued interest | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $574,592 |
15_Common_Stock_Details
15. Common Stock (Details) (USD $) | 6 Months Ended |
Mar. 31, 2014 | |
Issuance 1 | ' |
Stock Issued During Period, Shares, Other | 3,712,549 |
Stock Issued During Period, Value, Other | $2,447,857 |
Issuance 2 | ' |
Stock Issued During Period, Shares, Other | 584,100 |
Stock Issued During Period, Value, Other | 134,897 |
Issuance 3 | ' |
Stock Issued During Period, Shares, Other | 474,000 |
Stock Issued During Period, Value, Other | 400,585 |
Issuance 4 | ' |
Stock Issued During Period, Shares, Other | 161,738 |
Stock Issued During Period, Value, Other | 163,170 |
Issuance 5 | ' |
Stock Issued During Period, Shares, Other | 125,000 |
Stock Issued During Period, Value, Other | 110,000 |
Issuance 6 | ' |
Stock Issued During Period, Shares, Other | 60,000 |
Stock Issued During Period, Value, Other | 52,200 |
Issuance 7 | ' |
Stock Issued During Period, Shares, Other | 100,000 |
Stock Issued During Period, Value, Other | 85,000 |
Issuance 8 | ' |
Stock Issued During Period, Shares, Other | 342,930 |
Stock Issued During Period, Value, Other | 342,000 |
Issuance 9 | ' |
Stock Issued During Period, Shares, Other | 6,924,526 |
Issuance 9 | Series C Preferred Stock | ' |
Stock Issued During Period, Shares, Conversion of Units | 480,000 |
Issuance 9 | Series D Preferred Stock | ' |
Stock Issued During Period, Shares, Conversion of Units | 893,218 |
Issuance 10 | ' |
Stock Issued During Period, Shares, Other | 73,921 |
Stock Issued During Period, Value, Other | $68,245 |
16_Stock_Options_and_Warrants_2
16 Stock Options and Warrants: Schedule of Warrants Fair Value Assumptions (Details) (USD $) | 6 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Minimum | ' | ' |
Fair Value Assumptions, Exercise Price | $0.95 | $1 |
Fair Value Assumptions, Expected Term | '2 years | '2 years 6 months |
Fair Value Assumptions, Expected Volatility Rate | 213.00% | 223.00% |
Fair Value Assumptions, Risk Free Interest Rate | 0.28% | 0.35% |
Maximum | ' | ' |
Fair Value Assumptions, Exercise Price | $1.10 | $1.50 |
Fair Value Assumptions, Expected Term | '3 years | '5 years |
Fair Value Assumptions, Expected Volatility Rate | 216.00% | 298.00% |
Fair Value Assumptions, Risk Free Interest Rate | 0.71% | 0.88% |
16_Stock_Options_and_Warrants_3
16 Stock Options and Warrants (Details) (USD $) | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | |
Option grant 1 | Option grant 1 | Option grant 2 | Option grant 3 | Option grant 4 | Option grant 5 | Option grant 6 | |||||
Share-based compensation arrangement by share-based payment award, Options, Grants in period | ' | ' | 8,058,122 | ' | ' | 650,000 | 450,000 | 856,977 | 3,669,120 | 1,424,025 | 1,008,000 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | ' | ' | $1.09 | ' | ' | $1.10 | $1 | $1.10 | $1.10 | $1.10 | $1.10 |
Interest expense, net | $171,422 | $767,391 | $1,440,498 | $1,790,983 | $590,887 | ' | ' | ' | ' | ' | ' |
Debt Discount | ' | ' | ' | ' | ' | ' | $143,634 | ' | ' | ' | ' |
Weighted average remaining term of the warrants | 4.3 | ' | 4.3 | ' | ' | ' | ' | ' | ' | ' | ' |
16_Stock_Options_and_Warrants_4
16 Stock Options and Warrants: Schedule of Share-based Compensation, Activity (Details) (USD $) | 6 Months Ended |
Mar. 31, 2014 | |
Details | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | 3,598,554 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $1.33 |
Share-based compensation arrangement by share-based payment award, Options, Grants in period | 8,058,122 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $1.09 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | -1,058,100 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $1 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 10,598,576 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $1.18 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | 9,568,576 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $1.19 |
17_Segment_Information_Schedul1
17. Segment Information: Schedule of Segment Reporting Information, by Segment (Details) (USD $) | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2014 | Mar. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2013 | Sep. 30, 2013 | |
Total revenues | $1,090,951 | $4,713,124 | $3,519,209 | $7,086,416 | ' |
Net loss | -4,496,070 | -2,450,329 | -7,247,912 | -6,031,046 | ' |
Interest expense, net | 171,422 | 767,391 | 1,440,498 | 1,790,983 | ' |
Total assets | 10,755,815 | ' | 10,755,815 | ' | 12,374,050 |
Corporate1Member | ' | ' | ' | ' | ' |
Net loss | -2,382,809 | -2,011,486 | -5,179,511 | -4,302,830 | ' |
Interest expense, net | 171,422 | 767,391 | 1,440,498 | 1,790,983 | ' |
Total assets | 628,370 | 20,816 | 628,370 | 20,816 | ' |
Property and equipment purchases | 7,057 | ' | 58,145 | ' | ' |
Depreciation, Depletion and Amortization, Nonproduction | 26,259 | 179 | 56,092 | 357 | ' |
Chronic Illness Monitoring | ' | ' | ' | ' | ' |
Total revenues | 814,187 | 4,256,011 | 2,893,654 | 6,209,615 | ' |
Net loss | -1,867,630 | 455,392 | -1,519,988 | 224,157 | ' |
Total assets | 8,309,224 | 7,517,626 | 8,309,224 | 7,517,626 | ' |
Depreciation, Depletion and Amortization, Nonproduction | 28,610 | 28,610 | 57,220 | 57,220 | ' |
CareservicesMember | ' | ' | ' | ' | ' |
Total revenues | 276,764 | 457,113 | 625,555 | 876,801 | ' |
Net loss | -245,631 | -914,966 | -548,413 | -1,958,743 | ' |
Total assets | 1,818,221 | 3,255,691 | 1,818,221 | 3,255,691 | ' |
Property and equipment purchases | ' | 132,993 | ' | 266,522 | ' |
Depreciation, Depletion and Amortization, Nonproduction | 235,700 | 278,557 | 472,839 | 548,190 | ' |
ReagentsMember | ' | ' | ' | ' | ' |
Total revenues | ' | 130,029 | ' | 254,499 | ' |
Net loss | ' | 20,731 | ' | 6,370 | ' |
Total assets | ' | 161,064 | ' | 161,064 | ' |
Property and equipment purchases | ' | 888 | ' | 888 | ' |
Depreciation, Depletion and Amortization, Nonproduction | ' | 3,211 | ' | 6,451 | ' |
Total | ' | ' | ' | ' | ' |
Total revenues | 1,090,951 | 4,843,153 | 3,519,209 | 7,340,915 | ' |
Net loss | -4,496,070 | -2,450,329 | -7,247,912 | -6,031,046 | ' |
Interest expense, net | 171,422 | 767,391 | 1,440,498 | 1,790,983 | ' |
Total assets | 10,755,815 | 10,955,197 | 10,755,815 | 10,955,197 | ' |
Property and equipment purchases | 7,057 | 133,881 | 58,145 | 267,410 | ' |
Depreciation, Depletion and Amortization, Nonproduction | $290,569 | $310,557 | $586,151 | $612,218 | ' |
18_Commitments_and_Contingenci2
18. Commitments and Contingencies: Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $) | Mar. 31, 2014 |
Details | ' |
Operating Leases, Future Minimum Payments Due, Next Twelve Months | $152,539 |
Operating Leases, Future Minimum Payments, Due in Two Years | 308,330 |
Operating Leases, Future Minimum Payments, Due in Three Years | 317,580 |
Operating Leases, Future Minimum Payments, Due in Four Years | 327,107 |
Operating Leases, Future Minimum Payments, Due in Five Years | 280,077 |
Operating Leases, Future Minimum Payments Due | $1,385,633 |
18_Commitments_and_Contingenci3
18. Commitments and Contingencies (Details) (USD $) | 6 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Details | ' | ' |
Operating Leases, Rent Expense, Net | $150,000 | $107,000 |